Circulating immune cell landscape in patients who had mild ischaemic stroke

Abstract

IntroductionPatients who had a mild ischaemic stroke who present with subtle or resolving symptoms sometimes go undiagnosed, are excluded from treatment and in some cases clinically worsen. Circulating immune cells are potential biomarkers that can assist with diagnosis in ischaemic stroke. Understanding the transcriptomic changes of each cell population caused by ischaemic stroke is critical because they work closely in a complicated relationship. In this study, we investigated peripheral blood mononuclear cells (PBMCs) transcriptomics of patients who had a stroke using a single-cell RNA sequencing to understand peripheral immune response after mild stroke based on the gene expression in an unbiased way.MethodsTranscriptomes of PBMCsfrom 10 patients who had an acute ischaemic stroke within 24 hours after stroke onset were compared with 9 race-matched/age-matched/gender-matched controls. Individual PBMCs were prepared with ddSeqTM (Illumina-BioRad) and sequenced on the Illumina NovaSeq 6000 platform.ResultsNotable population changes were observed in patients who had a stroke, especially in NK cells and CD14+ monocytes. The number of NK cells was increased, which was further confirmed by flow cytometry. Functional analysis implied that the activity of NK cells also is enhanced in patients who had a stroke. CD14+ monocytes were clustered into two groups; dendritic cell-related CD14+ monocytes and NK cell-related CD14+ monocytes. We found CD14+ monocyte subclusters were dramatically reduced in patients who had a stroke.DiscussionThis is the first study demonstrating the increased number of NK cells and new monocyte subclusters of mild ischaemic stroke based on the transcriptomic analysis. Our findings provide the dynamics of circulating immune response that could assist diagnosis and potential therapeutic development of mild ischaemic stroke.

Clinical Potential of Immunotherapies in Subarachnoid Hemorrhage Treatment: Mechanistic Dissection of Innate and Adaptive Immune Responses

“…Innate immune cells include neutrophils, microglia, macrophages, mast cells (MCs), natural killer (NK) cells, dendritic cells (DCs), as well as specific types of lymphocytes. Immune recognition activates innate immune cells and a variety of effector responses [25][26][27]. The dominant effector response is pathogen elimination by phagocytosis and secretion of cytokines and proinflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and reactive oxygen species (ROS), which directly eliminate potential threats via a massive and undifferentiated inflammatory response [28].…”

Immunomodulatory role of estrogen in ischemic stroke: neuroinflammation and effect of sex

“…Stroke is associated with a significant increase in estrogen levels, which suggests an immediate physiological reaction following brain injury. The rapid, local production of estrogen has been reported to be associated with the activation of innate immunity ( 53 ). Reportedly, 17β-estradiol can inhibit the production and release of pro-inflammatory cytokines, including IL-1β, IL-6, and TNFα.…”

Neuroinflammation and brain–peripheral interaction in ischemic stroke: A narrative review

“…Such neuroinflammatory interaction will be intensified in a variety of neurological conditions, especially in stroke. It has been reported that peripheral immune cells can also be observed in the brain parenchyma after stroke onset ( 13 ). Therefore, it is necessary to fully examine the physiological interactions between the immune responses and brain injuries.…”

“…The expression of CXC3CR1 on NK cells is required for the recruitment of neutrophils, which is also dependent on the expression of interferon gamma (IFN-γ) ( 42 ). Moreover, according to a previous study, IFN-γ can be secreted from NK cells and recruit macrophages or dendritic cells, which are involved in secondary ischemic damage ( 13 ). However, there are also several conflicting reports on the biological role of NK cells in the progression of stroke.…”